For individuals that have treatment-resistant/significant depression and have experienced thoughts of self-harm, undergoing Ketamine Therapy is advised.
Eskretamine is a nasal spray that the FDA approved in March 2019. Since its approval and distribution for public use, it has helped numerous adults treat depression, especially when combined with an oral antidepressant. Spravato addresses treatment-resistant depression and helps manage depression symptoms and alleviate suicide ideation.
While ketamine has been known as s psychedelic drug, when it is used under the supervision of a licensed health professional, it can be perfectly safe and even save the lives of those who are showing signs of suicide ideation.
With Eskretamine being renowned for its positive effects in addressing depression symptoms, it has become widely covered by most major insurance providers. If you are interested in learning more about payments we receive for the treatments we offer, including the Esketamine nasal spray, please click on your state at our Locations tab.
Since ketamine is a psychedelic substance, individuals who use esketamine for their treatment may experience symptoms of feeling groggy or dizzy, intoxicated, or euphoric. Individuals who have just gotten the treatment are not advised to drive a vehicle, so they need to be accompanied by someone who can drive them to and from their treatment.
